These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, Ripamonti D, Cologni G, Fabbiani M, Caputo SL, Sighinolfi L, Ladisa N, El-Hamad I, Quiros-Roldan E, Frank I. Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996 [Abstract] [Full Text] [Related]
4. Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients. Chow WZ, Lim SH, Ong LY, Yong YK, Takebe Y, Kamarulzaman A, Tee KK. PLoS One; 2015 May; 10(9):e0137281. PubMed ID: 26335136 [Abstract] [Full Text] [Related]
5. Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort. Ndumbi P, Gillis J, Raboud JM, Cooper C, Hogg RS, Montaner JS, Burchell AN, Loutfy MR, Machouf N, Klein MB, Tsoukas CM, Canadian Observational Cohort (CANOC) collaboration. AIDS; 2013 Nov 28; 27(18):2863-72. PubMed ID: 25119689 [Abstract] [Full Text] [Related]
6. Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB, CANOC Collaboration. PLoS One; 2013 Nov 28; 8(10):e77665. PubMed ID: 24204912 [Abstract] [Full Text] [Related]
7. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting. Hermans SM, Manabe YC, Kiragga AN, Hoepelman AI, Lange JM, van Leth F. Antivir Ther; 2013 Nov 28; 18(4):615-22. PubMed ID: 23423604 [Abstract] [Full Text] [Related]
10. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study. Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534 [Abstract] [Full Text] [Related]
13. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC, Swiss HIV Cohort Study. Antivir Ther; 2007 Aug 01; 12(6):889-97. PubMed ID: 17926643 [Abstract] [Full Text] [Related]
14. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study. Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328 [Abstract] [Full Text] [Related]
19. Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy. Mutoh Y, Nishijima T, Inaba Y, Tanaka N, Kikuchi Y, Gatanaga H, Oka S. Clin Infect Dis; 2018 Aug 31; 67(6):927-933. PubMed ID: 29509894 [Abstract] [Full Text] [Related]